RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published its annual letter to stockholders on the Company's website at www.regenerx.com.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published its annual letter to stockholders on the Company's website at www.regenerx.com.
Editor in Chief, Warfield Digital
ConnectIndependent Consultant
ConnectPresident of Lawrence Howard & Associates
ConnectPartner at Womble Carlyle, LLP
ConnectOwner at Develop DC
ConnectStinson Marketing Group
Connect